



indoco remedies limited

INDOCO HOUSE, 166 C. S. T. ROAD, SANTACRUZ (EAST), MUMBAI - 400 098 (INDIA) ● Website : www.indoco.com
PHONES : (91-22) 6287 1000 / 3386 1250 ● CIN : L85190MH1947PLC005913 ● GSTIN : 27AAACI0380C1Z3

October 16, 2019


To Listing Department National Stock Exchange of India Limited 'Exchange Plaza', C - 1, Block G, Bandra-Kurla Complex, <u>Bandra (E), Mumbai 400051.</u> Scrip Code: INDOCO	To BSE Limited Corporate Relationship Department 1 st Floor, New Trading Ring, Phiroze Jeejeebhoy Towers Dalal Street <u>Mumbai 400001</u> Scrip Code : 532612
--	---

Dear Sirs,

Sub : Disclosure under Regulation 30 of LODR Regulations 2015
Indoco successfully concludes USFDA inspection at Goa Plant II

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find Press Release for your information and record.

For Indoco Remedies Limited


Jayshankar Menon
Company Secretary



PRESS RELEASE

Indoco successfully concludes USFDA inspection at Goa Plant II

Mumbai, October 16, 2019: The US Food and Drug Administration (USFDA) inspected Indoco's sterile manufacturing facility in Goa (Plant II) from 7th October to 15th October, 2019. The audit was concluded successfully.

"This is the second successful Pre-Approval Inspection (PAI) of this site in less than 6 months, which indicates steady progress in review of our pending ANDAs. The Company has 39 ANDAs pending for approval from this site", **said Ms. Aditi Kare Panandikar, Managing Director – Indoco Remedies Ltd.**

The Inspection ended with 2 observations, neither of these are related to Data Integrity or the core Quality Management System and the Company will respond to the FDA within the stipulated time. The site continues to maintain its VAI status.

About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 140 million Company, employs over 5500 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by USFDA, UK-MHRA, TGA-Australia, Cofepris – Mexico, etc. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from around 3,10,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include, Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensoform, Sensodent-KF, Karvol Plus, Glychek, Kidodent, Carmicide, Bactogard, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) – USA and ASPEN-South Africa.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:

Vilas V. Nagare

Mobile: 9820215745

E-mail: vilasn@indoco.com / corpcom@indoco.com